Synairgen (LON:SNG) Stock Price Down 16% – Here’s What Happened

Posted by ABMN Staff on Mar 19th, 2025

Synairgen plc (LON:SNG – Get Free Report) shares dropped 16% during mid-day trading on Monday . The company traded as low as GBX 0.73 ($0.01) and last traded at GBX 0.79 ($0.01). Approximately 920,817 shares were traded during trading, a decline of 37% from the average daily volume of 1,456,314 shares. The stock had previously closed at GBX 0.93 ($0.01).

Synairgen Stock Down 6.2 %

The firm’s fifty day simple moving average is GBX 1.91 and its 200-day simple moving average is GBX 3.25. The company has a market cap of £7.79 million, a PE ratio of -0.48 and a beta of -2.23.

Synairgen Company Profile

(Get Free Report)

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).